Eli Lilly and Company: Second Clinical Trial Substantiates Survival Benefit Associated with Xigris in Lilly's Pivotal Phase III Trial.
Business Wire › October 27, 2003
Linked as:
Extract
Eli Lilly and Company: Second Clinical Trial Substantiates Survival Benefit Associated with Xigris in Lilly's Pivotal Phase III Trial.
Business Editors/Health/Medical Writers
INDIANAPOLIS--(BUSINESS WIRE)--Oct. 27, 2003 EMBARGOED UNTIL TUESDAY, OCTOBER 28 @ 10:45 a.m. EST ENHANCE Study Corroborates Robust Treatment Effect Associated with Xigris in Adult Severe Sepsis Patients New research findings substantiate those observed in the la...See the full content of this document
Sponsored links
